Overview

Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease

Status:
Recruiting
Trial end date:
2020-12-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with Non-erosive gastroesphageal reflux disease.
Phase:
Phase 3
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited